Want to see HK:1951 full AI Analyst Report?
1951 Stock Chart & Stats
HK$2.21
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.21
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.92 - HK$3.61
Previous CloseN/A
Volume3.76M
Average Volume (3M)20.30M
Market Cap
HK$5.84B
Enterprise ValueHK$8.79K
Total Cash (Recent Filing)HK$906.17M
Total Debt (Recent Filing)HK$2.96B
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Sep 01, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend Yield1.93%
Share Statistics
EPS (TTM)-0.36
Shares Outstanding2,705,044,000
10 Day Avg. Volume21,878,483
30 Day Avg. Volume20,304,545
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio26.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.00Price Target Upside35.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.83B
Bulls Say, Bears Say
Bulls Say
Clinic Network & Business ModelA multi-clinic fertility services model creates durable revenue channels and operational scale. A distributed clinic network supports patient referrals, specialization and capacity utilization, making core service delivery and recovery less dependent on any single site over months.
Manageable LeverageLow-to-moderate debt levels provide financial flexibility to invest, absorb cyclical shocks or fund clinic upgrades without heavy refinancing risk. This balance-sheet room supports multi-month strategic actions like targeted expansion or service enhancement without excessive leverage pressure.
Core Cash Generation & MarginsSustainably positive operating and EBITDA margins indicate profitable service economics at the core. Combined with positive operating cash flow history, this suggests the business can generate cash from operations to support working capital and gradual reinvestment even while headline net income fluctuates.
Bears Say
2025 Profitability CollapseA sharp swing to a large net loss in 2025 materially weakens earnings durability. Even with positive underlying margins, a sustained or repeated revenue decline could erode reserves, constrain investment and raise uncertainty about the timing of recovery over the next several months.
Free Cash Flow DeteriorationA significant drop in free cash flow reduces internal funding for expansion, maintenance and dividends, increasing reliance on external financing. Over a multi-month horizon this limits strategic flexibility and can force tougher trade-offs between capex, working capital and shareholder returns.
Negative Return On EquityNegative ROE reflects the 2025 earnings hit and signals impaired shareholder returns. Persistently negative ROE can hinder capital-raising appetite and makes it harder to justify reinvestment, increasing pressure on management to restore profitability in the medium term.
Jinxin Fertility Group Ltd. News
1951 FAQ
What was Jinxin Fertility Group Ltd.’s price range in the past 12 months?
Jinxin Fertility Group Ltd. lowest stock price was HK$1.92 and its highest was HK$3.61 in the past 12 months.
What is Jinxin Fertility Group Ltd.’s market cap?
Jinxin Fertility Group Ltd.’s market cap is HK$5.84B.
When is Jinxin Fertility Group Ltd.’s upcoming earnings report date?
Jinxin Fertility Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 28 days.
How were Jinxin Fertility Group Ltd.’s earnings last quarter?
Jinxin Fertility Group Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.035 earnings per share for the quarter, the consensus estimate of HK$0.035 by HK$0.
Is Jinxin Fertility Group Ltd. overvalued?
According to Wall Street analysts Jinxin Fertility Group Ltd.’s price is currently Undervalued.
Does Jinxin Fertility Group Ltd. pay dividends?
Jinxin Fertility Group Ltd. pays a Notavailable dividend of HK$0.042 which represents an annual dividend yield of 1.93%. See more information on Jinxin Fertility Group Ltd. dividends here
What is Jinxin Fertility Group Ltd.’s EPS estimate?
Jinxin Fertility Group Ltd.’s EPS estimate is 0.03.
How many shares outstanding does Jinxin Fertility Group Ltd. have?
Jinxin Fertility Group Ltd. has 2,705,044,000 shares outstanding.
What happened to Jinxin Fertility Group Ltd.’s price movement after its last earnings report?
Jinxin Fertility Group Ltd. reported an EPS of HK$0.035 in its last earnings report, expectations of HK$0.035. Following the earnings report the stock price went up 2.681%.
Which hedge fund is a major shareholder of Jinxin Fertility Group Ltd.?
Currently, no hedge funds are holding shares in HK:1951
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jinxin Fertility Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.67%
12-Months-Change
Fundamentals
Return on Equity
1.93%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Jinxin Fertility Group Ltd.
Jinxin Fertility Group Ltd. (1951) is a China-based fertility services provider focused on assisted reproductive services. The group operates in the healthcare sector, providing services associated with fertility treatment, including assisted reproductive technology (ART) and related clinical services delivered through its network of fertility hospitals/clinics.
1951 Stock 12 Month Forecast
Average Price Target
HK$3.00
▲(35.75% Upside)
Technical Analysis
Aidigong Maternal & Child Health
―
Kindstar Globalgene Technology, Inc.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Concord Healthcare Group Co., Ltd. Class H
―